Press coverage about Fortress Biotech (NASDAQ:FBIO) has been trending somewhat positive on Thursday, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fortress Biotech earned a news impact score of 0.03 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.0829897216692 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
NASDAQ FBIO traded down $0.02 during mid-day trading on Thursday, hitting $5.08. The stock had a trading volume of 70,083 shares, compared to its average volume of 162,347. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.72 and a quick ratio of 2.71. The company has a market capitalization of $249.52, a P/E ratio of -3.16 and a beta of 0.23. Fortress Biotech has a 52-week low of $3.13 and a 52-week high of $5.54.
Several research firms recently weighed in on FBIO. HC Wainwright set a $11.00 price objective on Fortress Biotech and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Zacks Investment Research downgraded Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Monday, February 19th. ValuEngine raised Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. B. Riley began coverage on Fortress Biotech in a research note on Wednesday, February 28th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, BidaskClub raised Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Sunday, March 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.75.
Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.